AlphaFold predicted structure
SRD5A2 · P31213
Mean pLDDT
94.4/ 100
Very high
254 residues
Confidence breakdown
- Very high(≥ 90)88%
- Confident(70–90)9%
- Low(50–70)3%
- Very low(< 50)0%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
SRD5A2
Chr 2p23.1steroid 5 alpha-reductase 2
- MANE:
- ENST00000622030.2
Annotations refreshed 9 hours ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Diagnostic Grade (Green)
Differences in sex development
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomal
Disease associations (Open Targets)
46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency
0.84androgenetic alopecia
0.70benign prostatic hyperplasia
0.63prostate carcinoma
0.62prostate cancer
0.57hypotrichosis
0.46alopecia
0.42Micropenis
0.42hypogonadism
0.41prostate neoplasm
0.39
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
3-oxo-5-alpha-steroid 4-dehydrogenase 2
Catalyzes the irreversible stereospecific reduction of the delta 4,5 bond (double bond between carbons 4 and 5) of various 3-oxo steroids (3-keto steroids) producing their 5alpha dihydro-3-oxo forms (PubMed:10898110, PubMed:23685396). Converts testosterone into 5-alpha-dihydrotestosterone (DHT), the most active androgen in the prostate, as it is the preferred ligand for androgen receptor (AR) transactivation, making this reaction a key step in male sexual differentiation during development (PubMed:10898110, PubMed:23685396). Besides testosterone, it can also act on other steroids, including progesterone, producing metabolites with diverse roles (PubMed:10898110). Hence, it plays a central role in sexual differentiation and androgen physiology (PubMed:10898110)
Diseases associated with SRD5A2
Curated MONDO disease pages that list SRD5A2 among their top associated genes.